Back
Compare AU
Compare INES vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are INES and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
INES | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 20 | 65 |
Median incremental investment | $803.40 | $862.71 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,515.05 | $1,930.07 |
Average age group | > 35 | 26 - 35 |
Key Summary
INES | DRUG | |
|---|---|---|
Strategy | INES.AX was created on 2019-06-11 by Intelligent Investor . The fund's investment portfolio concentrates primarily on total market equity. To invest in a portfolio of ethically and socially responsible undervalued stocks to achieve medium to long-term capital growth. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Intelligent Investor Eth Share Fund - Active ETF (100 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Financials (42.50 %) Other (21.54 %) Communication Services (17.57 %) | Other (76.24 %) Communication Services (33.53 %) Health Care (23.57 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.97 % | 0.57 % |
Key Summary
INES | DRUG | |
|---|---|---|
Issuer | Intelligent Investor | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.97 % | 0.57 % |
Price | $3.68 | $7.59 |
Size | $75.760 million | $167.548 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | 3.38 % | 2.04 % |
Market | ASX | ASX |
First listed date | 12/06/2019 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
INES | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 20 | 65 |
Median incremental investment | $803.40 | $862.71 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,515.05 | $1,930.07 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
INES | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
INES | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |